Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

NCT03600818 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT03600818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03600818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Terminated
Start date
October 9, 2018
Completion date
May 19, 2021
Enrollment
118 (actual)
Sites
84

Conditions

As the registry lists them; a condition with its own page is linked.

polymyalgia rheumatica